Literature DB >> 29952809

Pulmonary Rehabilitation Only Versus With Nutritional Supplementation in Patients With Bronchiectasis: A RANDOMIZED CONTROLLED TRIAL.

Esperanza Doña1, Casilda Olveira, Francisco Javier Palenque, Nuria Porras, Antonio Dorado, Rocío Martín-Valero, Ana M Godoy, Francisco Espildora, Gabriel Olveira.   

Abstract

PURPOSE: Pulmonary rehabilitation (PR) is recommended for bronchiectasis, but there is little evidence of its efficacy in these patients. The aim of this study was to assess the effect of PR in normally nourished patients with noncystic fibrosis bronchiectasis compared with the effect of PR plus an oral nutritional supplement (PRONS).
METHODS: A single-center randomized controlled trial, parallel treatment design in which participants were randomly assigned to receive PR for 12 wk or PR plus a high-protein nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate. Outcome assessments were performed at baseline, 12 and 24 wk including cardiopulmonary exercise testing, health-related quality of life (HRQOL), bronchorrhea, dyspnea, psychological symptoms, spirometry, and exacerbations.
RESULTS: Thirty patients were randomized into 2 groups of 15 participants. In both groups, cardiopulmonary exercise testing, HRQOL, dyspnea, and spirometry parameters significantly increased from baseline at 3 and/or 6 mo.
CONCLUSION: PR improved exercise capacity, HRQOL, and respiratory parameters. The use of PRONS did not have a significant effect on the results.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29952809     DOI: 10.1097/HCR.0000000000000341

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  1 in total

1.  Osteopenia and Osteoporosis in Patients with Bronchiectasis: Association with Respiratory Parameters, Body Composition, Muscle Strength and Bone Remodeling Biomarkers.

Authors:  V Contreras-Bolívar; G Olveira; N Porras; E Acosta; E Rubio-Martín; M J Tapia-Guerrero; J Abuin-Fernández; C Olveira
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.